Versican silencing improves the antitumor efficacy of endostatin by alleviating its induced inflammatory and immunosuppressive changes in the tumor microenvironment

Wang,Zi; Li,Zhixi; Wang,Yuyi; Cao,Dan; Wang,Xia; Jiang,Ming; Li,Mei; Yan,Xi; Li,Yan; Liu,Yanyang; Luo,Feng

doi:10.3892/or.2015.3903

Versican silencing improves the antitumor efficacy of endostatin by alleviating its induced inflammatory and immunosuppressive changes in the tumor microenvironment

Authors:
- Zi Wang
- Zhixi Li
- Yuyi Wang
- Dan Cao
- Xia Wang
- Ming Jiang
- Mei Li
- Xi Yan
- Yan Li
- Yanyang Liu
- Feng Luo
View Affiliations

Affiliations: Department of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan 61004, P.R. China
Published online on: April 7, 2015 https://doi.org/10.3892/or.2015.3903
Pages: 2981-2991

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The systematic application of antiangiogenic therapy remains an issue of concern, mainly due to the hypoxic and inflammatory changes in the tumor microenvironment elicited by antiangiogenic therapy. Versican, a ‘bridge’ connecting inflammation with tumor progression as well as playing a central role in the generation of an inflammatory tumor microenvironment is a promising candidate for the intervention of inflammatory changes in the tumor microenvironment elicited by antiangiogenic therapy. To examine this hypothesis, a short‑hairpin RNA targeting versican (shVCAN) was designed and shVCAN stable‑transfected B16F1 and Lewis lung carcinoma (LLC) cell lines were established. Simultaneously, the established B16F1 and LLC tumor models were used to investigate the effect of versican silencing on the tumor burden of mice. The results showed that, versican silencing exerted an inhibitory effect on the proliferative and migratory ability of B16F1 cells, but did not affect LLC cells. Endostatin exhibited modest inhibition of tumor growth in tumor-bearing mice. Versican silencing alone effectively suppressed orthotopic tumor growth and significantly prolonged survival time of mice more effectively when combined with endostatin. Endostatin elicited inflammatory and immunosuppressive changes in the tumor microenvironment, including an accumulation of myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs) and inflammatory cytokines. In addition, NF-κB and HIF-1α were overexpressed in the tumor. Versican silencing improved the antitumor efficacy of endostatin by alleviating its induced changes in the tumor microenvironment. Thus, versican silencing in the tumor microenvironment offers a promising approach to reverse the tumor refractoriness to antiangiogenic therapies.

View Figures

View References

1	Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, Qian DZ, Yancopoulos GD and Pili R: Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res. 13:4201–4208. 2007. View Article : Google Scholar : PubMed/NCBI
2	Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D and Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15:220–231. 2009. View Article : Google Scholar : PubMed/NCBI
3	Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L and Mikkelsen T: Efficacy, safety and patterns of response and recurrence in patients with recurrent highgrade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 91:329–336. 2009. View Article : Google Scholar
4	Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP and Ferrara N: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b⁺Gr1⁺ myeloid cells. Nat Biotechnol. 25:911–920. 2007. View Article : Google Scholar : PubMed/NCBI
5	Soeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, Abe M and Sato A: Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol. 109:122–128. 2008. View Article : Google Scholar : PubMed/NCBI
6	Kischel P, Waltregny D, Dumont B, Turtoi A, Greffe Y, Kirsch S, De Pauw E and Castronovo V: Versican overexpression in human breast cancer lesions: Known and new isoforms for stromal tumor targeting. Int J Cancer. 126:640–650. 2010. View Article : Google Scholar
7	Wang W, Xu GL, Jia WD, Ma JL, Li JS, Ge YS, Ren WH, Yu JH and Liu WB: Ligation of TLR2 by versican: A link between inflammation and metastasis. Arch Med Res. 40:321–323. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL and Karin M: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 457:102–106. 2009. View Article : Google Scholar : PubMed/NCBI
9	Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, Sadik H, Argani P, Wagner P, Vahdat LT, et al: Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 72:1384–1394. 2012. View Article : Google Scholar : PubMed/NCBI
10	Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, Chen Y and Guo QL: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 361:79–84. 2007. View Article : Google Scholar : PubMed/NCBI
11	Wang HL, Ning T, Li M, Lu ZJ, Yan X, Peng Q, Lei N, Zhang H and Luo F: Effect of endostatin on preventing postoperative progression of distant metastasis in a murine lung cancer model. Tumori. 97:787–793. 2011.
12	Ning T, Yan X, Lu ZJ, Wang GP, Zhang NG, Yang JL, Jiang SS, Wu Y, Yang L, Guan YS, et al: Gene therapy with the angiogenesis inhibitor endostatin in an orthotopic lung cancer murine model. Hum Gene Ther. 20:103–111. 2009. View Article : Google Scholar
13	Ning T, Jiang M, Peng Q, Xi Y, Lu ZJ, Peng YL, Wang HL, Lei N, Zhang H, Lin HJ, et al: Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model. Thorac Cancer. 3:229–238. 2012. View Article : Google Scholar
14	Huang G and Chen L: Discrepancies between antiangiogenic and antitumor effects of recombinant human endostatin. Cancer Biother Radiopharm. 24:589–596. 2009. View Article : Google Scholar : PubMed/NCBI
15	Zhang H, Wang Z, Peng Q, Liu YY, Zhang W, Wu L, Wang X and Luo F: Tumor refractoriness to endostatin anti-angiogenesis is associated with the recruitment of CD11b+Gr1+ myeloid cells and inflammatory cytokines. Tumori. 99:723–733. 2013.
16	Li XQ, Shang BY, Wang DC, Zhang SH, Wu SY and Zhen YS: Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth. Cancer Lett. 301:212–220. 2011. View Article : Google Scholar : PubMed/NCBI
17	Ben-Neriah Y and Karin M: Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol. 12:715–723. 2011. View Article : Google Scholar : PubMed/NCBI
18	Hernández D, Miquel-Serra L, Docampo MJ, Marco-Ramell A and Bassols A: Role of versican V0/V1 and CD44 in the regulation of human melanoma cell behavior. Int J Mol Med. 27:269–275. 2011.
19	Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS and Yang BB: Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J. 18:754–756. 2004.PubMed/NCBI
20	Ostrand-Rosenberg S and Sinha P: Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol. 182:4499–4506. 2009. View Article : Google Scholar : PubMed/NCBI
21	Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
22	Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, Meng YG and Ferrara N: G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA. 106:6742–6747. 2009. View Article : Google Scholar : PubMed/NCBI
23	Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, Abbruzzese JL and Melisi D: Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res. 17:5822–5832. 2011. View Article : Google Scholar : PubMed/NCBI
24	Gordon S and Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol. 5:953–964. 2005. View Article : Google Scholar : PubMed/NCBI
25	Pollard JW: Trophic macrophages in development and disease. Nat Rev Immunol. 9:259–270. 2009. View Article : Google Scholar : PubMed/NCBI
26	Sica A and Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 117:1155–1166. 2007. View Article : Google Scholar : PubMed/NCBI
27	Martinez FO, Helming L and Gordon S: Alternative activation of macrophages: An immunologic functional perspective. Annu Rev Immunol. 27:451–483. 2009. View Article : Google Scholar
28	Mantovani A, Bottazzi B, Colotta F, Sozzani S and Ruco L: The origin and function of tumor-associated macrophages. Immunol Today. 13:265–270. 1992. View Article : Google Scholar : PubMed/NCBI
29	Mantovani A and Sica A: Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr Opin Immunol. 22:231–237. 2010. View Article : Google Scholar : PubMed/NCBI
30	Qian BZ and Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell. 141:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
31	Sica A, Saccani A and Mantovani A: Tumor-associated macrophages: A molecular perspective. Int Immunopharmacol. 2:1045–1054. 2002. View Article : Google Scholar : PubMed/NCBI
32	Kim YJ, Jung EB, Lee MS, Seo SJ, Kim MH, Lee MW and Lee CS: Rotundarpene inhibits toll-like receptor 2 activation-induced production of inflammatory mediators in keratinocytes by suppressing the Akt and NF-κB pathways. Int Immunopharmacol. 18:325–332. 2014. View Article : Google Scholar : PubMed/NCBI